Dr. Laura Soucek


Co-Founder and Chief Executive Officer (CEO) of Peptomyc S.L. Principal Investigator of the Mouse Models of Cancer Therapies Group at the Vall d´Hebron Institute of Oncology (VHIO) and ICREA Professor.

Dr. Soucek is a leading figure in the Myc field and has pioneered studies on MYC inhibition since designing Omomyc when she was still an undergraduate student. Dr. Soucek has published in top scientific journals including Nature, Nature Medicine, Genes & Development, and Nature Communications as First and Senior author. Since early 2011, Dr. Soucek heads the Mouse Models of Cancer Therapies Group at the Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain. Although her VHIO lab is relatively young (5 years), she has already published extensively as Principal Investigator in high impact journals. Moreover, her research has already been recognized through several national research awards and grants (FERO fellowship, grants from the Miguel Servet Program, FIS and AGAUR), and prestigious international grants such as an ERC Consolidator grant (2014-2019), and an AICR (now Worldwide Cancer Research) grant. She is also co-inventor of two patent applications including the one at the basis of this project. In December 2014, she co-founded Peptomyc S.L. As CEO of Peptomyc S.L., she will direct the scientific aspects of the project (which is closely related to the ERC project ongoing in the lab that enabled the preliminary steps of the current innovation project) oversee its overall implementation, progress, and success.

Relevant publications:

  1. Soucek, L., Helmer-Citterich, M., Sacco, A., Jucker, R., Cesareni, G., and Nasi, S. (1998). Oncogene 17, 2463-2472.
  2. Soucek, L., Jucker, R., Panacchia, L., Ricordy, R., Tato, F., and Nasi, S. (2002). Cancer Research 62, 3507-3510.
  3. Annibali, D., Whitfield, J.R., Favuzzi, E., Jauset, T., Serrano, E., Cuartas, I., Redondo-Campos, S., Folch, G., Gonzalez-Junca, A., Sodir, N.M., et al. (2014). Nature Communications 5, 4632.
  4. Sodir, N.M., Swigart, L.B., Karnezis, A.N., Hanahan, D., Evan, G.I., and Soucek, L. (2011). Genes & Development 25, 907-916.
  5. Soucek, L., Nasi, S., and Evan, G.I. (2004). Cell Death and Differentiation 11, 1038-1045.
  6. Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J., Murphy, D.J., Sodir, N.M., Karnezis, A.N., Swigart, L.B., Nasi, S., and Evan, G.I. (2008). Nature 455, 679-683.
  7. Soucek, L., Whitfield, J.R., Sodir, N.M., Masso-Valles, D., Serrano, E., Karnezis, A.N., Swigart, L.B., and Evan, G.I. (2013). Genes & Development 27, 504-513.
  8. Savino, M., Annibali, D., Carucci, N., Favuzzi, E., Cole, M.D., Evan, G.I., Soucek, L., and Nasi, S. (2011). PloS One 6, e22284.

back to top

Dr. Marie-Eve Beaulieu


Co-Founder & Chief Scientific Officer (CSO) of Peptomyc S.L. Senior Postdoctoral Fellow in Dr. Soucek’s Mouse Models of Cancer Therapies Group at the Vall d´Hebron Institute of Oncology (VHIO). 

Dr. Beaulieu has extensive experience in biochemistry and structural biology of b-HLH-LZ transcription factors (such as Omomyc) and peptide design. In parallel to her academic career, she worked with the pharmaceutical industry and studied peptide formulations using various biophysical methods such as Nuclear Magnetic Resonance, Circular Dichroism and Fluorescence spectroscopies. She graduated in November 2011 (PhD in Pharmacology, Université de Sherbrooke, Canada), and was awarded several competitive fellowships (CREFSIP scholarship grant (PhD project), MITACS Accelerated postdoctoral fellowship (postdoc project at Theratechnologies Inc., Montreal, Canada) and a FRSQ postdoctoral award from the Quebec government (current postdoc project)). She already co-authored 13 peer-reviewed publications and 2 book chapters. In 2012, she joined Dr. Soucek’s laboratory as a postdoctoral fellow and unveiled the cell-penetrating properties of the purified Omomyc peptide. She is co-inventor of the patent application protecting the use of Omomyc in medicine and co-founder of Peptomyc S.L. with the aim of translating years of academic research into a practical value for society. As CSO of Peptomyc, she will coordinate the activities performed by the CROs and perform and supervise the activities related to the Omomyc peptide development (preclinical validation in vitro and in vivo) within the lab.

back to top

Antares Consulting


Antares Consulting is a boutique Consulting firm specialized in health care. Their strong experience in spin-off creation and regulatory affairs makes them a highly valued partner.


back to top

Vantum Corporate


Vantum Corporate (CFO).


back to top